10th Congress of the
European Association of Dermato-Oncology
Targeting CD30 in PTCL:
the why, which, and how
10 May 2014 9:30–10:30
Radisson Blu Hotel, Vilnius, Lithuania
Zeta Room, 1st Floor

Learning objectives

09:30–09:35 Welcome and introduction
Andreas Engert

09:35–09:50 What is the rationale for targeting CD30 in sALCL and cutaneous T-cell lymphoma?
Andreas Engert – Germany

09:50–10:05 What is the clinical evidence and what are the ongoing trials for CD30-targeting agents?
Timothy Illidge – UK

10:05–10:25 Case presentation:
How to optimize the management of sALCL patients in daily practice
Christian Gisselbrecht – France

10:25–10:30 Closing

 

Chair:

Andreas Engert
Germany
Faculty:

Timothy Illidge
UK

Christian Gisselbrecht
France
This meeting is an
Excerpta Medica activity.
logos
Support for this educational activity is provided by
Takeda Oncology.
logos